The Chicago-based marketer is joining forces with Vesifact, which is headquartered in Baar, Switzerland and is a spin-off from the Swiss Federal Institute of Technology in Zurich. The alliance is looking to hold-up the patented Vesisorb delivery system - the first joint product of which will be branded CoQsource bio-enhanced CoQ10. The companies claim that thanks to the technology, peak absorption results for CoQsource achieved a peak of 16.97 percent in a clinical study. It reports that studies involving other CoQ10 ingredients - in powder, oil dispersion and lipid solution delivery systems - revealed absorption rates of 2.15 percent, 3.34 percent, and 5.44 percent. Developed by Vesifact, the Vesisorb system is protected worldwide by multiple US and International granted and pending patents. SourceOne's role will now be as exclusive worldwide marketing and distribution partner for Vesifact. Though beginning with CoQ10, the agreement will continue to include a range of proprietary branded products all drawing on the Vesisorb technology. "SourceOne, together with our Swiss partner, Vesifact, is extremely proud to introduce bio-enhanced ingredients and proprietary formulas containing CoQ10 in both the ubiquinone and ubiquinol forms, as well as Omegasmart high potency EPA and DHA, Sytrinol, PMFsource citrus bioflavonoids, Tocosource palm tocotrienols, and other proprietary formulas that make up our Cholesstrinol family of products," said SourceOne president and CEO, Jesse Lopez. CoQ10 has been studied for its role in cognitive health and heart health. It plays a vital role in the production of chemical energy in mitochondria - the cell's 'power plants' - by participating in the production of adenosince triphosphate (ATP), the body's co-called 'energy currency'.